On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of Major Depressive Disorder in adults.

(CORRECTION: In the mechanism section, it is SIGMA RECEPTOR AGONISM & NOT ANTAGONISM)

We have summarized this FDAapproved medication in the following
Psychiatry Education Forum Academy Updates:

Read Details: https://psychiatryeducationforum.com/...